GSK to buy pulmonary hypertension biotech 35Pharma for $950M

Ali Nemati5 days ago27 sec read49 views

GlaxoSmithKline (GSK) acquired 35Pharma for $950 million to gain access to their pulmonary hypertension drug program, expanding GSK's therapeutic portfolio. This move is significant as it enhances GSK’s presence in specialized pharmaceutical markets and opens potential avenues for research into weight loss treatments. Content creators should note the growing interest of major pharma companies in niche biotech innovations, which may influence future healthcare content trends.

Read the full article at Endpoints News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Comments

Abcuro drug fails muscle weakness trial, development to continue

Abcuro's experimental drug missed its primary and key secondary endpoints in a Phase 2b/3 trial for treating a rare autoimmune condition without FDA-a...Abcuro's experimental drug missed its primary and key secondary endpoints in a Phase 2b/3 trial for treating a rare autoimmune condition without FDA-approved therapies. Despite the setback, Abcuro plans to continue development, highlighting the persi...

Ali Nemati

Biotech & Pharma5 days ago31 sec read

Immedica wins accelerated approval for once-rejected rare disease drug

Swedish biotech Immedica received FDA accelerated approval for a drug addressing elevated plasma arginine levels in patients with the rare disease ARG...Swedish biotech Immedica received FDA accelerated approval for a drug addressing elevated plasma arginine levels in patients with the rare disease ARG1-D, marking a significant breakthrough after initial rejection. This approval offers new hope and t...

Ali Nemati

Biotech & Pharma6 days ago28 sec read

AI biotech Turbine raises $25M Series B to sell 'Virtual Lab' to pharma

Budapest-based biotech company Turbine secured $25 million in Series B funding to advance its 'Virtual Lab' technology, which simulates cell behavior ...Budapest-based biotech company Turbine secured $25 million in Series B funding to advance its 'Virtual Lab' technology, which simulates cell behavior using AI models, aiming to revolutionize pharmaceutical research processes. This investment undersco...

Ali Nemati

Biotech & Pharma6 days ago31 sec read

Astellas pays $240M cash for Vir's prostate cancer drug

Astellas Pharma agreed to pay $240 million in cash to Vir Biotechnology for an experimental prostate cancer drug, marking a significant deal as Vir tr...Astellas Pharma agreed to pay $240 million in cash to Vir Biotechnology for an experimental prostate cancer drug, marking a significant deal as Vir transitions its focus towards oncology. This partnership underscores the growing interest in innovativ...

Ali Nemati

Biotech & Pharma2 days ago27 sec read

STAT+: Pharmalittle: We're reading about FDA and a 'smear campaign,' Cigna buying a large pharmacy, and more

The U.S. FDA Commissioner Marty Makary defended recent rejections of rare disease drugs and top official Vinay Prasad against a perceived "smear campa...The U.S. FDA Commissioner Marty Makary defended recent rejections of rare disease drugs and top official Vinay Prasad against a perceived "smear campaign," while Cigna acquired CarepathRx to strengthen its control over pharmaceutical distribution in ...

Ali Nemati

GSK to buy pulmonary hypertension biotech 35Pharma for $950M

Related Articles

Abcuro drug fails muscle weakness trial, development to continue

Immedica wins accelerated approval for once-rejected rare disease drug

AI biotech Turbine raises $25M Series B to sell 'Virtual Lab' to pharma

Astellas pays $240M cash for Vir's prostate cancer drug

STAT+: Pharmalittle: We're reading about FDA and a 'smear campaign,' Cigna buying a large pharmacy, and more